Abstract |
This multicenter, open-label phase 2 trial determined the safety and efficacy of carfilzomib, a novel and irreversible proteasome inhibitor, in combination with cyclophosphamide and dexamethasone ( CCyd) in patients with newly diagnosed multiple myeloma (NDMM) ≥65 years of age or who were ineligible for autologous stem cell transplantation. Patients (N = 58) received CCyd for up to 9 28-day cycles, followed by maintenance with carfilzomib until progression or intolerance. After a median of 9 CCyd induction cycles (range 1-9), 95% of patients achieved at least a partial response, 71% achieved at least a very good partial response, 49% achieved at least a near complete response, and 20% achieved stringent complete response. After a median follow-up of 18 months, the 2-year progression-free survival and overall survival rates were 76% and 87%, respectively. The most frequent grade 3 to 5 toxicities were neutropenia (20%), anemia (11%), and cardiopulmonary adverse events (7%). Peripheral neuropathy was limited to grades 1 and 2 (9%). Fourteen percent of patients discontinued treatment because of adverse events, and 21% of patients required carfilzomib dose reductions. In summary, results showed high complete response rates and a good safety profile. This trial was registered at clinicaltrials.gov as #NCT01346787.
|
Authors | Sara Bringhen, Maria Teresa Petrucci, Alessandra Larocca, Concetta Conticello, Davide Rossi, Valeria Magarotto, Pellegrino Musto, Luana Boccadifuoco, Massimo Offidani, Paola Omedé, Fabiana Gentilini, Giovannino Ciccone, Giulia Benevolo, Mariella Genuardi, Vittorio Montefusco, Stefania Oliva, Tommaso Caravita, Paola Tacchetti, Mario Boccadoro, Pieter Sonneveld, Antonio Palumbo |
Journal | Blood
(Blood)
Vol. 124
Issue 1
Pg. 63-9
(Jul 03 2014)
ISSN: 1528-0020 [Electronic] United States |
PMID | 24855212
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 by The American Society of Hematology. |
Chemical References |
- Oligopeptides
- carfilzomib
- Dexamethasone
- Cyclophosphamide
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cyclophosphamide
(administration & dosage, adverse effects)
- Dexamethasone
(administration & dosage, adverse effects)
- Disease-Free Survival
- Female
- Humans
- Kaplan-Meier Estimate
- Male
- Multiple Myeloma
(drug therapy, mortality)
- Oligopeptides
(administration & dosage, adverse effects)
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|